knowledge -WSS

knowledge

author：comprehensive 2025-09-14 18:25:34 - browse：54918

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Congress may force more Covid

leisure time

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

There's no autism epidemic. It's an autism diagnosis epidemic

Study says nonprofit hospitals fall short in charity care spending

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Ukraine seeks to reclaim its role as a hub for clinical trials

Surprise medical billing ban raises prices elsewhere

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

A new drug could help frostbite victims avoid its ravages

DIEP, the 'gold standard' of breast reconstruction, is under threat

As AI regulations shape up, health tech startups beg for clarity

Medicare details structure of new drug price negotiation program

A new drug could help frostbite victims avoid its ravages

Heart attack and stroke risk calculators need revising

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Anesthesiologist group: stop taking Ozempic before surgery

Why the world’s most expensive drug might be worth the price

hotspot

Steward Health Care has deal to sell doctor network to UnitedHealth

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

MD Anderson's Padmanee Sharma responds to research credit suit

Abridge raises $150m as clinical notes automation market heats up

As AI regulations shape up, health tech startups beg for clarity

Measles policy set amid Florida outbreak alarms vaccine proponents

focus

leisure time

focus

leisure time